Search

Your search keyword '"Zhang, Xuepei"' showing total 281 results

Search Constraints

Start Over You searched for: Author "Zhang, Xuepei" Remove constraint Author: "Zhang, Xuepei"
281 results on '"Zhang, Xuepei"'

Search Results

11. Impaired oxygen-sensitive regulation of mitochondrial biogenesis within the von Hippel–Lindau syndrome

12. What Happens to the Preserved Renal Parenchyma After Clamped Partial Nephrectomy?

13. Multifaceted Proteome Analysis at Solubility, Redox, and Expression Dimensions for Target Identification.

17. Adding Color to Mass Spectra of Biopolymers: Charge Determination Analysis (CHARDA) Assigns Charge State to Every Ion Peak

19. A chemical inhibitor of IST1-CHMP1B interaction impairs endosomal recycling and induces noncanonical LC3 lipidation

21. Assessing the Feasibility and Safety of the Toumai® Robotic System in Urologic Surgery: Initial Experience.

22. A DBN Approach to Predict the Link in Opportunistic Networks

26. MAEL in human cancers and implications in prognostication and predicting benefit from immunotherapy over VEGFR/mTOR inhibitors in clear cell renal cell carcinoma: a bioinformatic analysis

28. Publisher Correction: Impaired oxygen-sensitive regulation of mitochondrial biogenesis within the von Hippel–Lindau syndrome

29. Ultralight Ultrafast Enzymes

31. Multifaceted proteome analysis at solubility, redox, and expression dimensions for target identification

33. Chemogenetic inhibition of IST1-CHMP1B interaction impairs endosomal recycling and promotes unconventional LC3 lipidation at stalled endosomes

35. Ultralight Ultrafast Enzymes.

40. PD07-06 RENAL TUMOR PLANAR EXTENSION IN THREE-DIMENSIONAL MODEL AS A NOVEL TECHNIQUE FOR PREOPERATIVE ASSESSMENT OF ROBOTIC PARTIAL NEPHRECTOMY

41. Table S3 from Camrelizumab plus Famitinib in Patients with Advanced or Metastatic Renal Cell Carcinoma: Data from an Open-label, Multicenter Phase II Basket Study

42. Figure S1 from Camrelizumab plus Famitinib in Patients with Advanced or Metastatic Renal Cell Carcinoma: Data from an Open-label, Multicenter Phase II Basket Study

43. Supplementary Data from Camrelizumab plus Famitinib in Patients with Advanced or Metastatic Renal Cell Carcinoma: Data from an Open-label, Multicenter Phase II Basket Study

Catalog

Books, media, physical & digital resources